	US 12,410,219 B2
	Polypeptide derived from CAP1 and pharmaceutical composition comprising same as effective ingredient
Hyo Soo Kim, Seoul (KR); Hyun Duk Jang, Seoul (KR); and Sang Eun Lee, Seoul (KR)
Assigned to SEOUL NATIONAL UNIVERSITY HOSPITAL, Seoul (KR)
Filed by Seoul National University Hospital, Seoul (KR)
Filed on Jul. 6, 2021, as Appl. No. 17/368,090.
Application 17/368,090 is a continuation in part of application No. 16/482,333, granted, now 11,091,515, previously published as PCT/KR2018/001332, filed on Jan. 31, 2018.
Claims priority of application No. 10-2017-0014128 (KR), filed on Jan. 31, 2017.
Prior Publication US 2022/0033452 A1, Feb. 3, 2022
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01); A61P 1/16 (2006.01); A61P 3/08 (2006.01)

CPC C07K 14/4703 (2013.01) [A61P 1/16 (2018.01); A61P 3/08 (2018.01); A61K 38/00 (2013.01)]

8 Claims

1. A method for treating inflammatory bowel disease (IBD), rheumatoid arthritis (RA), breast cancers, diabetes, fatty hepatitis, or atherosclerosis; or inhibiting cancer metastasis; in a subject in need thereof, the method comprising administering a composition comprising an effective amount of a peptide consisting of SEQ ID NO: 1 (GPPPPPVSTS), SEQ ID NO: 2 (PPPPGPPPPPVSTSSGSDES), SEQ ID NO: 4 (AAAAGPPPPPVSTSSGSDES), or SEQ ID NO: 5 (PPPPGAAAAAVSTSSGSDES) as an active ingredient to the subject in need thereof.